urovestВестник урологииUrology Herald2308-6424Rostov State Medical University10.21886/2308-6424-2026-14-1-131-138urovest-1195Research ArticleОБЗОРЫ ПУБЛИКАЦИЙ – ТЕКУЩЕЕ МНЕНИЕCURRENT STATE-OF-THE-ARTПобочные эффекты внутрипузырной иммунотерапии БЦЖ и методы их ликвидацииIntravesical BCG immunotherapy: adverse effects and management strategieshttps://orcid.org/0000-0001-8060-6691КорчагинМ. П.KorchaginM. P.

Михаил Павлович Корчагин

Москва

Korchagin M. Pavlovich

Moscow

mihailsun@mail.ruhttps://orcid.org/0009-0009-7448-3934ЛиЮ. А.LiIu. A.

Юлия Августовна Ли

Москва

Iuliia A. Li

Moscow

julee1806@gmail.comhttps://orcid.org/0000-0001-6513-9888ДымовА. М.DymovA. M.

Алим Мухамедович Дымов — д-р. мед. наук, профессор

Москва

Alim M. Dymov — Dr.Sc.(Med), Full Prof.

Moscow

alimdv@mail.ruНациональный медицинский исследовательский центр онкологии им. Н.Н. БлохинаРоссияBlokhin National Medical Research Centre for OncologyRussian FederationПервый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский университет)РоссияSechenov First Moscow State Medical University (Sechenov University)Russian Federation202605042026141131138Copyright © Корчагин М.П., Ли Ю.А., Дымов А.М., 20262026Корчагин М.П., Ли Ю.А., Дымов А.М.Korchagin M.P., Li I.A., Dymov A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.urovest.ru/jour/article/view/1195

Согласно современным клиническим рекомендациям пациентам с немышечно-инвазивным раком мочевого пузыря (НМИРМП) промежуточного и высокого риска показано проведение внутрипузырной БЦЖ-терапии. Однако одним из существенных ограничений БЦЖ-терапии является высокая частота возникновения нежелательных явлений, в том числе урогенитального туберкулёза. Целью работы послужила систематизация наиболее часто встречающихся побочных эффектов внутрипузырной БЦЖ-терапии и способов уменьшения токсичности препарата, а также алгоритмов лечения нежелательных явлений.

In accordance with contemporary clinical guidelines, intravesical BCG immunotherapy is indicated for patients with intermediate‑ and high‑risk non‑muscle‑invasive bladder cancer (NMIBC). Nonetheless, its use is constrained by a considerable burden of adverse events, notably urogenital tuberculosis. This study therefore sought to synthesise current evidence on the most observed complications of intravesical BCG therapy, approaches to reducing treatment‑related toxicity, and structured algorithms for the management of BCG‑associated adverse events.

БЦЖ-терапиярак мочевого пузыряонкоурологияурогенитальный туберкулёзBCG therapybladder cancerurologic oncologyurogenital tuberculosisИсследование не имело спонсорской поддержки.The study was not sponsored.ReferencesСостояние онкологической помощи населению России в 2024 году. Под ред. Каприна А.Д., Старинского В.В., Шахзадовой А.О. Москва: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2025.Kaprin A.D., Starinsky V.V., Shakhzadova A.O., eds. State of Cancer Care in Russia in 2024. Moscow: P.A. Herzen Moscow Oncology Research Institute – Branch of the National Medical Research Centre for Radiology of the Ministry of Health of the Russian Federation; 2025. (In Russian).Lu JL, Xia QD, Lu YH, Liu Z, Zhou P, Hu HL, Wang SG. Efficacy of intravesical therapies on the prevention of recurrence and progression of non-muscle-invasive bladder cancer: A systematic review and network meta-analysis. Cancer Med. 2020;9(21):7800-7809. Erratum in: Cancer Med. 2021;10(16):5722. DOI: 10.1002/cam4.3513Lu JL, Xia QD, Lu YH, Liu Z, Zhou P, Hu HL, Wang SG. Efficacy of intravesical therapies on the prevention of recurrence and progression of non-muscle-invasive bladder cancer: A systematic review and network meta-analysis. Cancer Med. 2020;9(21):7800-7809. Erratum in: Cancer Med. 2021;10(16):5722. DOI: 10.1002/cam4.3513Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmetteguerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005;174(1):86-91; discussion 91-2. DOI: 10.1097/01.ju.0000162059.64886.1cSylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmetteguerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005;174(1):86-91; discussion 91-2. DOI: 10.1097/01.ju.0000162059.64886.1cДымов А.М., Ли Ю.А., Корчагин М.П., Джаримок А.Р., Винаров А.З., Газимиев М.А. БЦЖ-терапия пациентов с немышечно-инвазивным раком мочевого пузыря: как обстоят дела? Урология. 2024;(2):116- 120.Dymov A.M., Lee Y.A., Korchagin M.P., Dzharimok A.R., Vinarov A.Z., Gazimiev M.A. BCG-therapy for non-muscle-invasive bladder cancer: overview of the current trends. Urologiia. 2024;(2):116-120. (In Russian). DOI: 10.18565/urology.2024.2.116-120Green DB, Kawashima A, Menias CO, Tanaka T, Redelman-Sidi G, Bhalla S, Shah R, King BF. Complications of Intravesical BCG Immunotherapy for Bladder Cancer. Radiographics. 2019;39(1):80-94. DOI: 10.1148/rg.2019180014Green DB, Kawashima A, Menias CO, Tanaka T, Redelman-Sidi G, Bhalla S, Shah R, King BF. Complications of Intravesical BCG Immunotherapy for Bladder Cancer. Radiographics. 2019;39(1):80-94. DOI: 10.1148/rg.2019180014Griffin JG, Holzbeierlein J. Side effects of perioperative intravesical treatment and treatment strategies for these side effects. Urol Clin North Am. 2013;40(2):197-210. DOI: 10.1016/j.ucl.2013.01.005Griffin JG, Holzbeierlein J. Side effects of perioperative intravesical treatment and treatment strategies for these side effects. Urol Clin North Am. 2013;40(2):197-210. DOI: 10.1016/j.ucl.2013.01.005Cabas P, Rizzo M, Giuffrè M, Antonello RM, Trombetta C, Luzzati R, Liguori G, Di Bella S. BCG infection (BCGitis) following intravesical instillation for bladder cancer and time interval between treatment and presentation: A systematic review. Urol Oncol. 2021;39(2):85-92. DOI: 10.1016/j.urolonc.2020.11.037Cabas P, Rizzo M, Giuffrè M, Antonello RM, Trombetta C, Luzzati R, Liguori G, Di Bella S. BCG infection (BCGitis) following intravesical instillation for bladder cancer and time interval between treatment and presentation: A systematic review. Urol Oncol. 2021;39(2):85-92. DOI: 10.1016/j.urolonc.2020.11.037Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124-1129. PMID: 10737480Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124-1129. PMID: 10737480Wan der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV; EORTC Genito-Urinary Tract Cancer Group. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol. 2003;44(4):429-434. DOI: 10.1016/s0302-2838(03)00357-9Wan der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV; EORTC Genito-Urinary Tract Cancer Group. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol. 2003;44(4):429-434. DOI: 10.1016/s0302-2838(03)00357-9Thyavihally YB, Dev P, Waigankar S, Pednekar A, Athikari N, Raut A, Khandekar A, Badlani N, Asari A. Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer-analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I). Asian J Urol. 2022;9(2):157-164. DOI: 10.1016/j.ajur.2021.05.002Thyavihally YB, Dev P, Waigankar S, Pednekar A, Athikari N, Raut A, Khandekar A, Badlani N, Asari A. Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer-analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I). Asian J Urol. 2022;9(2):157-164. DOI: 10.1016/j.ajur.2021.05.002Vilares AT, Nunes Silva C, Correia da Silva M, Sousa J, Viamonte B, Madureira AJ. Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer. Radiol Case Rep. 2022;17(7):2383- 2387. DOI: 10.1016/j.radcr.2022.04.022Vilares AT, Nunes Silva C, Correia da Silva M, Sousa J, Viamonte B, Madureira AJ. Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer. Radiol Case Rep. 2022;17(7):2383- 2387. DOI: 10.1016/j.radcr.2022.04.022Pérez-Jacoiste Asín MA, Fernández-Ruiz M, López-Medrano F, Lumbreras C, Tejido Á, San Juan R, Arrebola-Pajares A, Lizasoain M, Prieto S, Aguado JM. Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore). 2014;93(17):236-254. DOI: 10.1097/MD.0000000000000119Pérez-Jacoiste Asín MA, Fernández-Ruiz M, López-Medrano F, Lumbreras C, Tejido Á, San Juan R, Arrebola-Pajares A, Lizasoain M, Prieto S, Aguado JM. Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore). 2014;93(17):236-254. DOI: 10.1097/MD.0000000000000119Holmes BJ, larue RW, Black JH 3rd, Dionne K, Parrish NM, Melia MT. Mycotic aortic aneurysm due to intravesical BCG immunotherapy: Clinical manifestations and diagnostic challenges. Int J Mycobacteriol. 2014;3(1):60-65. DOI: 10.1016/j.ijmyco.2013.11.002Holmes BJ, larue RW, Black JH 3rd, Dionne K, Parrish NM, Melia MT. Mycotic aortic aneurysm due to intravesical BCG immunotherapy: Clinical manifestations and diagnostic challenges. Int J Mycobacteriol. 2014;3(1):60-65. DOI: 10.1016/j.ijmyco.2013.11.002Choi SY, Ha MS, Kim JH, Chi BH, Kim JW, Chang IH, Kim TH, Myung SC. Low-dose versus standard-dose bacille Calmette-Guérin for non-muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized controlled trials. Investig Clin Urol. 2022;63(2):140-150. DOI: 10.4111/icu.20210340Choi SY, Ha MS, Kim JH, Chi BH, Kim JW, Chang IH, Kim TH, Myung SC. Low-dose versus standard-dose bacille Calmette-Guérin for non-muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized controlled trials. Investig Clin Urol. 2022;63(2):140-150. DOI: 10.4111/icu.20210340Jasmer RM, McCowin MJ, Webb WR. Miliary lung disease after intravesical bacillus Calmette-Guérin immunotherapy. Radiology. 1996;201(1):43-44. DOI: 10.1148/radiology.201.1.8816518Jasmer RM, McCowin MJ, Webb WR. Miliary lung disease after intravesical bacillus Calmette-Guérin immunotherapy. Radiology. 1996;201(1):43-44. DOI: 10.1148/radiology.201.1.8816518Anis O, Yogev D, Dotan A, Tsur AM, David P, Vishnevskia Dai V, Laufer M, Dotan Z, Shoenfeld Y. Autoimmune disorders caused by intravesical bacillus Calmette-Guerine treatment: A systematic review. Autoimmun Rev. 2023;22(6):103329. DOI: 10.1016/j.autrev.2023.103329Anis O, Yogev D, Dotan A, Tsur AM, David P, Vishnevskia Dai V, Laufer M, Dotan Z, Shoenfeld Y. Autoimmune disorders caused by intravesical bacillus Calmette-Guerine treatment: A systematic review. Autoimmun Rev. 2023;22(6):103329. DOI: 10.1016/j.autrev.2023.103329Bassi P, Spinadin R, Carando R, Balta G, Pagano F. Modified induction course: a solution to side-effects? Eur Urol. 2000;37 Suppl 1:31-32. DOI: 10.1159/000052380Bassi P, Spinadin R, Carando R, Balta G, Pagano F. Modified induction course: a solution to side-effects? Eur Urol. 2000;37 Suppl 1:31-32. DOI: 10.1159/000052380Nagai T, Okamura T, Tanaka Y, Moritoki Y, Kobayashi D, Kobayashi T, Akita H, Yasui T. Evaluation of the Dwell-Time and Dose Difference in Intravesical Bacillus Calmette-Guèrin Therapy. Asian Pac J Cancer Prev. 2019;20(5):1389-1392. DOI: 10.31557/APJCP.2019.20.5.1389Nagai T, Okamura T, Tanaka Y, Moritoki Y, Kobayashi D, Kobayashi T, Akita H, Yasui T. Evaluation of the Dwell-Time and Dose Difference in Intravesical Bacillus Calmette-Guèrin Therapy. Asian Pac J Cancer Prev. 2019;20(5):1389-1392. DOI: 10.31557/APJCP.2019.20.5.1389Andius P, Fehrling M, Holmäng S. Intravesical bacillus Calmette-Guèrin therapy: experience with a reduced dwell-time in patients with pronounced side-effects. BJU Int. 2005;96(9):1290-1293. DOI: 10.1111/j.1464-410X.2005.05817.xAndius P, Fehrling M, Holmäng S. Intravesical bacillus Calmette-Guèrin therapy: experience with a reduced dwell-time in patients with pronounced side-effects. BJU Int. 2005;96(9):1290-1293. DOI: 10.1111/j.1464-410X.2005.05817.xColombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol. 2006;176(3):935-939. DOI: 10.1016/j.juro.2006.04.104Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol. 2006;176(3):935-939. DOI: 10.1016/j.juro.2006.04.104Pak S, Kim SY, Kim SH, Joung JY, Park WS, Chung J, Lee KH, Seo HK. Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer. Front Oncol. 2021;11:570077. DOI: 10.3389/fonc.2021.570077Pak S, Kim SY, Kim SH, Joung JY, Park WS, Chung J, Lee KH, Seo HK. Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer. Front Oncol. 2021;11:570077. DOI: 10.3389/fonc.2021.570077Rodríguez Faba Ó, Fernández Gómez JM, Guerrero-Ramos F, ÁlvarezMaestro M, Ledo Cepero MJ, Unda Urzaiz M, Martínez-Piñeiro L, Cózar Olmo JM, Redorta JP, Álvarez-Ossorio JL. Consensus document on the implications of standardization of BCG supply in the management of patients with non-muscle-invasive bladder cancer. Actas Urol Esp (Engl Ed). 2024;48(10):718-731. (In English, Spanish). DOI: 10.1016/j.acuroe.2024.09.005Rodríguez Faba Ó, Fernández Gómez JM, Guerrero-Ramos F, ÁlvarezMaestro M, Ledo Cepero MJ, Unda Urzaiz M, Martínez-Piñeiro L, Cózar Olmo JM, Redorta JP, Álvarez-Ossorio JL. Consensus document on the implications of standardization of BCG supply in the management of patients with non-muscle-invasive bladder cancer. Actas Urol Esp (Engl Ed). 2024;48(10):718-731. (In English, Spanish). DOI: 10.1016/j.acuroe.2024.09.005

The authors declare that there are no conflicts of interest present.